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The existence of human Ia antigen specificities distinct  from those of the system of 
DR alleles has been documented  (1).  More recently, polyclonal human allosera have 
been  used  to  define  the  MT  and  MB  systems  of alleles  (2,  3)  and  monoclonal 
antibodies recognizing specificities related to certain of the MT and MB determinants 
have  been  described  (4). 1  Although  important  questions  concerning  the  precise 
molecular and  genetic  basis  of the  Ia  specificities  remain  unanswered,  evidence  is 
accumulating that many of the alloantigens presumably occur on distinct  molecules 
under the control of separate genes (5-9). 1 
Despite the association of murine viral leukemogenesis with certain major hist0com- 
patibility  complex  haplotypes  (10)  in  man,  a  considerable  effort  has  not  revealed 
evidence of a  strong association between  HLA A, B, or DR alleles  and susceptibility 
to  chronic  lymphocytic  leukemia  or  other  common  forms  of malignancy  (11-15). 
However,  because  in  certain  families,  multiple  instances  of chronic  lymphocytic 
leukemia or Hodgkin's disease were correlated with the inheritance of particular HLA 
haplotypes  (16,  17),  the  possibility  remained  that  previously  unstudied  alleles  of 
histocompatibility loci, such as the non-DR Ia specificities,  might be associated with 
this susceptibility. The present study was undertaken among individuals with chronic 
lymphocytic leukemia to explore this hypothesis. 
Materials  and Methods 
Population Characterization.  The diagnosis of chronic lymphocytic leukemia was made in 29 
American Caucasians by conventional blood and bone marrow examination and the presence 
of a monoclonal proliferation of B lymphocytes. 48% of the individuals were considered to be 
of Jewish extraction. 30% were Rai stage 0,  15% stage I, 20% stage II, 15% stage III, and 20% 
stage  IV.  Healthy  laboratory and  administration  personnel  served  as  controls.  They were 
selected before study to include a similar percentage of ethnically matched persons. The average 
age of the control population was 33; that of the study was 60.3. 
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Cell Separation and Immunofluorescent Staining Techniques.  The mononuclear cells and enrich- 
ment for B cells by depletion of T  cells through binding to sheep erythrocytes was performed 
as described (18). The isotype of the monoclonal antibody IVD12 was IgG1, 109d6 IgG2a, and 
22C6 IgG2a. The monoclonal reagents were used in indirect immunofluorescence as undiluted 
supernatants  containing  20-40  #g  of antibody/ml.  Control  reagents  included  monoclonal 
antibodies of the  same  isotype with  irrelevant  specificities. 0.020  ml  of  the  supernatant 
containing the monoclonal antibody was added to 0.5-1 ×  105 cells in a V-bottomed microtiter 
plate (Cooke Laboratories, Alexandria, VA) and microimmunofluorescence staining was per- 
formed as described (19). F(ab')2 fragments of rabbit anti-mouse Ig antibodies that were directly 
conjugated with tetramethylrhodamine isothiocyanate were used in the second step. Specificity 
controls to detect interference by the IgG Fc receptor and analysis of the stained cells were 
performed by established procedures (18).  The criterion used for determining positivity was 
staining of >90% of the lymphocytes stained by the monomorphic anti Ia reagent 22c6 (19). 
Negativity was defined as staining of <5% of the Ia  + lymphocytes. 
Histocompatibility Typing and Statistical Analysis.  HLA DR 1-10 and MT1/MB1, MT2,3, and 
I~IB2 typing was performed using the standard National Institutes of Health microlymphocy- 
totoxicity assay with 7th and 8th International Histocompatibility Workshop reagents as well 
as with locally available sera (20). The chi square with Yates correction was used. The relative 
risk according to  Woolf, or ratio of conditional probabilities of disease in  the  presence or 
absence of the marker was used as described (20),  except that  in  the case where fractional 
values were obtained,  the  reciprocal of the  decimal  fraction  was  used  and  preceded by  a 
negative sign. 
Results 
Using alloantisera and  allospecific monoclonal  reagents,  individuals with  B  type 
chronic lymphocytic leukemia were found to have similar profiles of allodeterminants 
(Table I). Of the 29  individuals, 27  reacted positively with  the monoclonal reagent 
IVD 12, 26 were MT2+,  and  18 expressed the DR5 alloantigen. Of the 11 individuals 
lacking DR5, seven were DR4+.  All individuals with chronic lymphocytic leukemia 
were either MT2+  or IVD12+, and 24 bore both allodeterminants. Reciprocally, the 
occurrence of individuals bearing MT 1/MB 1 or DR2 was infrequent. 
Comparison of the  frequency of Ia  alloantigens with  a  control  group  of normal 
individuals studied at the same time revealed a  significant alteration in the frequency 
of several allodeterminants, as illustrated in Table II. Statistically significant positive 
associations were  found  with  the  antigens  detected  by  the  monoclonal  antibody 
IVD 12, relative risk  13.5, and with DR5  and MT2  determinants, respective relative 
risks  of  6.0  and  4.8.  The  use  of  the  lower  reported  frequency  for  MT2  among 
Caucasians  (21)  resulted  in  a  relative risk of 7.2.  In  contrast,  significant  negative 
associations were found with the presence of MT 1/MB 1 and DR2, respective relative 
risks of-8.1  and  -7.5.  No significant associations were  encountered  with  the  DR 
allospecificities 1,  3,  4, w6, or  7.  In both  the control and  leukemic populations, the 
presence  of  MT3  detected  by  microcytotoxicity paralleled  the  detection  of  the 
determinant by the monoclonal reagent  109d6 using immunofluorescence. However, 
the frequencies did not significantly differ between the two populations. 
Discussion 
The principal findings of this study were that individuals with chronic lymphocytic 
leukemia differed significantly from a  control population in the frequency of various 
Ia allodeterminants, and that strong positive and negative associations were evident 
with  Ia allospecificities that  were  not  alleles of the  DR  system.  These  observations 
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TABLE  I 
Frequent Occurrence of Certain Ia A lloantigenic Determinants among 29 Individuals with B Cell Type 
Chromc Lymphocytic Leukemia 
la alloantigen  phenotype 
Number  of 
individuals  with 
each  phenotype 
Microcytoxicity  with  alloantisera 
Immunolluorescence  with 
monoclonal  antibodies 
HLA-DR  Non-DR  specificities 
109d6  IVD  12 
specificities  MTI/MB1  MT2  MT3 
4  5,  --  +  --  --  + 
1  5,  --  +  +  +  + 
1  5,1  +  +  --  --  + 
2  5,2  +  +  --  --  + 
3  5,3  --  +  --  --  + 
2  5,4  --  +  +  +  + 
4  5,7  --  +  +  +  + 
1  5,w8  --  +  --  --  + 
1  4,  --  +  +  +  + 
1  4,1  +  --  +  +  + 
2  4,3  -  +  +  +  + 
1  4,w6  --  +  +  +  + 
2  4,7  --  --  +  +  + 
2  w6,  -  +  -  --  + 
1  w6,wl0  +  +  -  -  -- 
1  1,3  +  +  -  -  - 
TABLE II 
Contrasting Frequencies of Certain Ia Alloantzgenic Determinants between Individuals 
with Chronic Lymphocytic Leukemia and a Control Population 
Individuals 
Ia ailoantigen  Chi  square  (Yates)  Relative  risk  specificity  with  Leukemia  Normal  control 
n  =  29  n  =  28 
% posaive 
DRI  10.3  21.4  -2.4 
DR2  6.9  35.7  5.48  (P<  0.05)  -7.5 
DR3  20.7  25.0  -  1.3 
DR4  31.0  25.0  +1.4 
DR5  62.1  21.4  8.08  (P <  0.005)  +6.0 
DRW6  13.8  17.9  -1.4 
DR7  20.7  21.4  -1.0 
DRW8  3.4  0 
DRWI0  3.4  0 
MT1  20.7  67.9  11.04  (l' <  0.001)  -8.1 
MT2  89.7  64.3  3.88  (P <  0.05)  +4.8 
MT3  48.3  50.0  -  1.1 
109d6  48.3  50.0  -  1.1 
IVDI2  93.1  50.0  ll.06  (P<  0.001)  +13.5 
bility complex  that  influence the susceptibility or resistance  to chronic lymphocytic 
leukemia. 
The  two  monoclonal  antibodies,  IVD12  and  109d6,  that  reacted  with  Ia  gene- 
encoded determinants were the subject of a  separate report.1  In summary, the pattern 
of reactivity of I09d6 resembled that of the MT3 specificity (3) with positive reactions 
given by the B  cells of all normal individuals who were  DR4 + or DR7 +  (r =  0.943). 
The IVD 12 determinant was identified on B  cells of all DR4 +, most DR5 + (r =  0.820 
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generally similar to that  of the  MB3  determinant  (2).  Evidence  has been obtained 
that  each  antigen  detected  by  the  monoclonal  reagents  was  found  on  molecules 
distinct from one another and from those bearing the DR4 or DR5 specificities. 1 The 
provisional  haplotypic  association  of the  putative  genes  encoding  the  separate  Ia 
specificities were MT2  and  IVD12  in  association with  DR5,  and  MT3/109d6  and 
IVD12 in association with DR4. 
Among individuals with chronic lymphocytic leukemia, the most frequent inferred 
haplotype  was  that  associated  with  the  antigens  IVD12,  MT2,  and  DRS.  Four 
individuals  appeared  to  be  homozygous  for  this  Ia  haplotype.  Among  the  other 
individuals positive for both IVD12 and MT2 that  lacked DR5, the putative genes 
encoding IVD 12 and MT2 were each provided by a  different homologous chromo- 
some. It appears most likely that  the altered frequency of DR  alleles among those 
with  leukemia  is  attributable  to  the  haplotypic  associations  with  the  non-DR  Ia 
determinants. 
Further support for this possibility comes from certain earlier studies that reported 
a  decrease  in  the  frequency of a  DR2-1ike specificity  (22)  and  an  increase  in  the 
frequency of the alleles DR4 and DRw6  (23).  These alterations are consistent with 
the increase in the frequency of haplotypes containing either MT2 or IVD 12 among 
those with leukemia. This finding of a  primary association of disease susceptibility 
with alleles of the MT and MB series provides further support for the separate genetic 
control of these determinants and suggests the possibility that these or related gene 
products have functions distinct from those of the DR molecules. 
Possible additional evidence favoring an influence of genes in the Ia system on the 
susceptibility identified  in  this report can be inferred from the  lower percentage of 
leukemic deaths attributed to chronic lymphocytic leukemia among Japanese, 2.9%, 
compared with 31.5% among American Caucasians (24). Although the frequency of 
IVD12  is  not  defined  in  different  populations,  the  frequency  of  DR5,  the  DR 
alloantigen associated with IVD 12 and MT2, is 4.3% among the Japanese and  18.8% 
among American Caucasians (21). 
Summary 
The  Ia  antigen  allospecificities  of individuals  with  B  type  chronic  lymphocytic 
leukemia  differed  significantly  from  those  of a  control  population.  A  monoclonal 
antibody,  IVD12,  directed  to  a  MB3-1ike  determinant,  reacted  with  92.5%  of the 
individuals with leukemia and yielded the greatest positive relative risk, 13.5. A lower 
degree of positive association was found with the presence of the MT2 determinant. 
In  contrast,  the  low  observed  frequency  of  the  MT1/MB1  determinant  among 
leukemic individuals was associated with the most significant negative relative risk, 
-8.1.  Among HLA-DR specificities, the relative risk associated with the presence of 
DR5 was positive while that with DR2 was negative. 
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